Berbamine Exerts an Anti-oncogenic Effect on Pancreatic Cancer by Regulating Wnt and DNA Damage-related Pathways

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Pancreatic cancer remains a significant global health challenge with limited effective treatments.
• Understanding novel therapeutic agents and their mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the anti-pancreatic cancer effects of berbamine.
• To elucidate the molecular mechanisms underlying berbamine's action in pancreatic cancer cells.
• To evaluate the in vivo efficacy of berbamine in a preclinical pancreatic cancer model.

Main Methods:

• In vitro studies involved treating pancreatic cancer cell lines (BxPC3, PANC-1) with varying concentrations of berbamine.
• Assays included cell viability, colony formation, cell cycle analysis, and apoptosis detection.
• Western blotting, immunofluorescence, and a mouse xenograft model were used to explore mechanisms and in vivo effects.

Main Results:

• Berbamine significantly suppressed pancreatic cancer cell proliferation and colony formation.
• It induced cell cycle arrest and apoptosis, evidenced by increased γ-H2AX and Cleaved Caspase 3, and decreased Ki-67.
• In vivo, berbamine inhibited tumor growth in a mouse xenograft model, reducing β-catenin and increasing γ-H2AX expression.

Conclusions:

• Berbamine demonstrates significant anti-pancreatic cancer activity in vitro and in vivo.
• Its therapeutic potential may stem from the regulation of Wnt signaling and DNA damage response pathways.
• Berbamine represents a promising candidate for further development as a pancreatic cancer therapeutic.